Drug Profile
Pariglasgene brecaparvovec - Dimension Therapeutics
Alternative Names: AAV gene therapy - Dimension; AAV8G6PC; Adeno-associated virus vector gene therapy - Dimension; DTX-401Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Dimension Therapeutics
- Developer Dimension Therapeutics; Ultragenyx Pharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference; Glucose-6-phosphatase alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Glycogen storage disease type I
Most Recent Events
- 31 Dec 2023 Ultragenyx Pharmaceutical has patent protection for pariglasgene brecaparvovec in USA
- 17 Feb 2023 Ultragenyx completes enrolment in its phase III trial for Glycogen storage disease type I (In Adolescent, In children, In adults, In the elderly) in Netherland, Spain and Denmark
- 31 Dec 2022 European Medicines Agency (EMA) Committee accepts Pediatric Investigation Plan for Pariglasgene brecaparvovec for Glycogen storage disease